University of Pittsburgh
Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
The research agreement will support a potential IND for the therapy and help move the treatment into clinical testing in HER2-positive solid tumors, including ovarian cancer.
Genomic Test IDs Pancreatic Cysts Likely to Progress to Cancer Better Than Standard Guidelines
UPitt is hoping the latest data demonstrating the utility of its 22-gene PancreaSeq test will help drive adoption and reimbursement.
UPMC, Avalon GloboCare Ink Partnership to Advance CAR T-Cell Treatments
Researchers at the university will use Avalon's FLASH-CAR technology to speed up the development of treatments and improve their efficacy against cancer cells.
The proof-of-principle study demonstrated the feasibility of altering the microbiome to elicit anti-PD-1 response and shed light on which patients might benefit.
OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck Cancer
The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.